Global Biobanks Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In July 2023, Sweden implemented a revised Biobank Act, representing a contemporary update to the existing legislation. While upholding its primary goal of regulating the collection, storage, and ethical usage of identifiable human biological material for approved purposes, the new act aims to address and clarify uncertainties present in the original 2003 law. This modernization effort is designed to improve the understanding and interpretation of the regulations governing biobanking practices in Sweden.

• In June 2023, Denmark, Lithuania, and Switzerland received official confirmation of their membership in the Biobanking and BioMolecular resources Research Infrastructure – European Research Infrastructure Consortium (BBMRI-ERIC). Lithuania and Switzerland transitioned from their previous status as Observers to achieving full Membership, while Denmark has newly joined as an Observer.

The bioactive peptide market is segmented by source into animal, plant, and synthetic origins. Animal-derived peptides dominate the market due to their high bioavailability and efficacy, commonly extracted from milk, eggs, or fish. Plant-based peptides, obtained from sources like soy and wheat, are growing in demand, driven by consumer preference for natural and sustainable ingredients. Synthetic peptides, designed for targeted applications, are gaining traction in pharmaceutical and cosmetic industries due to their precision in formulation and scalability in production.

The market is also categorized by therapeutic area, including cardiovascular health, metabolic disorders, gastrointestinal health, and immune function. Cardiovascular health peptides are extensively studied for their role in reducing hypertension and cholesterol levels, propelling their adoption in functional foods and pharmaceuticals. Metabolic disorder peptides, such as those aiding in glucose regulation, are key drivers in addressing the rising prevalence of diabetes. Meanwhile, peptides targeting gastrointestinal and immune health are becoming essential in preventive healthcare, supported by the increasing consumer awareness of gut-immune health interconnection

Geographically, the market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America leads the market due to advanced research infrastructure, a well-established pharmaceutical industry, and growing consumer demand for functional foods. Europe follows closely, emphasizing innovations in peptide-based therapeutics. The Asia-Pacific region is emerging as a significant market, driven by growing investments in biotechnology and increasing health awareness among its large population base. Latin America and the Middle East & Africa, while smaller markets, show potential due to their growing healthcare infrastructures and increasing interest in natural health solutions.

Global Biobanks Segment Analysis

In this report, the Global Biobanks Market has been segmented by Media, Services, Application, and Geography.

Global Biobanks Market, Segmentation by Media

The Global Biobanks Market has been segmented by Media into Optimized Media and Non-Optimized Media.

Optimized media dominate the global biobanks market due to their superior ability to preserve the viability and integrity of biological samples for extended periods. These media are tailored with advanced formulations to support specific types of samples, such as stem cells, DNA, RNA, or plasma, ensuring minimal degradation during storage. The demand for optimized media is driven by advancements in regenerative medicine, personalized healthcare, and precision research, where high-quality, reliable samples are critical. Key innovations include cryoprotective agents and temperature-stable solutions that enhance sample preservation and usability.

Non-optimized media, while less advanced, continue to play a significant role in the market, particularly in cost-sensitive environments or for short-term storage applications. These media include basic preservation solutions without specialized additives, making them more affordable and accessible for smaller biobanks and research facilities. Although they lack the enhanced stability and performance of optimized media, non-optimized solutions are suitable for standard research processes, particularly in settings where high precision is not critical. However, their market share is gradually declining as demand for high-performance storage solutions grows.

The increasing focus on quality assurance and reproducibility in biobanking has led to a growing preference for optimized media, particularly in high-stakes applications like clinical trials and drug development. Regulatory requirements and international standards, such as ISO certifications for biobanks, further fuel the adoption of advanced media. Non-optimized media remain relevant in emerging markets and academic settings, where cost constraints limit the use of premium products. Overall, the shift towards optimized media is reshaping the market landscape, driving innovation and growth in storage solutions tailored to diverse scientific needs.

Global Biobanks Market, Segmentation by Services

The Global Biobanks Market has been segmented by Services into Human Tissue Biobanking, Stem Cell Biobanking, Cord Banking, DNA/RNA Biobanking, and Others.

Human tissue biobanking involves the collection, storage, and management of human tissues, such as biopsies, surgical specimens, and post-mortem samples. These biobanks are essential for research into disease mechanisms, drug development, and personalized medicine. By preserving tissues in optimal conditions, human tissue biobanks provide valuable resources for histological and molecular studies, enabling scientists to understand disease pathology and develop targeted therapies.

Stem cell biobanking focuses on the storage of stem cells, including embryonic stem cells, induced pluripotent stem cells (iPSCs), and adult stem cells. Stem cells have the unique ability to differentiate into various cell types, making them crucial for regenerative medicine, cell therapy, and tissue engineering. Stem cell biobanks support research aimed at developing treatments for a range of conditions, from neurodegenerative diseases to cardiac disorders.

Cord banking, also known as umbilical cord blood banking, involves the preservation of umbilical cord blood, which is rich in hematopoietic stem cells. These stem cells can be used in the treatment of blood disorders, such as leukemia and lymphoma, as well as certain genetic diseases. Cord banking provides a valuable resource for families and researchers, offering the potential for life-saving treatments and advancements in stem cell therapy.

DNA/RNA biobanking focuses on the preservation of genetic material, including DNA and RNA, from various biological samples. These biobanks are essential for genomics research, genetic testing, and the study of hereditary diseases. By maintaining high-quality genetic material, DNA/RNA biobanks enable researchers to conduct detailed analyses of genetic variations, gene expression, and molecular pathways, contributing to advancements in precision medicine and personalized healthcare.

The others category encompasses a range of additional biobanking services that support various research and clinical needs. This may include biobanking of biofluids, such as blood and plasma, microbiome samples, and other specialized biological materials. These services enhance the versatility and comprehensiveness of biobanks, ensuring they can meet the diverse demands of the scientific and medical communities.

Global Biobanks Market, Segmentation by Application

The Global Biobanks Market has been segmented by Application into Regenerative Medicine, Drug Discovery, and Disease Research.

Regenerative medicine relies heavily on biobanks to provide high-quality biological samples necessary for developing new therapies aimed at repairing or replacing damaged tissues and organs. Biobanks store stem cells, tissues, and other biological materials that are vital for regenerative medicine research and applications. These resources enable scientists to explore innovative treatments for conditions such as spinal cord injuries, heart disease, and degenerative disorders, pushing the boundaries of medical possibilities.

In drug discovery, biobanks play a crucial role by supplying well-characterized biological samples that are essential for identifying and validating new drug targets. The availability of diverse and high-quality samples accelerates the screening of potential drug candidates and facilitates preclinical testing, ultimately shortening the drug development timeline. By providing access to genetic material, cell lines, and tissue samples, biobanks help pharmaceutical companies and research institutions develop more effective and personalized medications, addressing a wide range of diseases.

Disease research benefits immensely from biobanking by enabling the study of disease mechanisms, epidemiology, and the identification of biomarkers. Biobanks store samples from patients with various diseases, allowing researchers to conduct retrospective and prospective studies. This wealth of biological data helps in understanding the genetic, molecular, and environmental factors contributing to disease onset and progression. Biobanks are instrumental in advancing knowledge about diseases, leading to better diagnostic tools, preventive strategies, and therapeutic approaches.

Global Biobanks Market, Segmentation by Geography

In this report, the Global Biobanks Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Biobanks Market Share (%), by Geographical Region, 2024

North America holds a significant share of the biobanks market, driven by robust research infrastructure, substantial funding, and a strong regulatory framework. The presence of leading biobanking organizations, extensive collaborations between academic institutions and industry, and a high prevalence of biobank-supported research contribute to the region's dominance. The United States and Canada are key contributors, with numerous biobanks supporting diverse research initiatives in genomics, personalized medicine, and disease research.

Europe is another major player in the global biobanks market, characterized by extensive biobanking networks and collaborative projects. The European Union's supportive policies and funding programs, such as Horizon Europe, enhance biobanking activities across the region. Countries like the United Kingdom, Germany, and France are at the forefront, hosting some of the world's largest and most advanced biobanks. These biobanks facilitate research and innovation in various medical fields, including regenerative medicine and drug discovery.

The Asia Pacific region is experiencing rapid growth in the biobanks market, fueled by increasing investments in biotechnology and healthcare infrastructure. Countries such as China, Japan, and India are expanding their biobanking capabilities to support burgeoning research activities and clinical applications. The region's large population base and diverse genetic pool provide valuable resources for disease research and the development of personalized therapies. Additionally, government initiatives and international collaborations are accelerating the establishment and expansion of biobanks in this region.

The Middle East and Africa region is emerging as an important market for biobanking, with growing recognition of the importance of biobanks in addressing regional health challenges. Countries such as the United Arab Emirates and South Africa are investing in biobanking infrastructure to support research and improve healthcare outcomes. Biobanks in this region are focusing on prevalent diseases and genetic disorders, aiming to enhance diagnostic capabilities and develop targeted treatments.

Latin America is also witnessing growth in the biobanks market, driven by increasing research activities and the establishment of biobanking facilities. Countries like Brazil, Mexico, and Argentina are enhancing their biobanking infrastructure to support local and international research collaborations. Biobanks in this region play a crucial role in studying genetic diversity and disease patterns unique to the Latin American population, contributing to global health research and the development of region-specific medical interventions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Biobanks Market. These factors include; Market Drivers, Restraints, and Opportunities.

Drivers, Restraints and Opportunity Analysis

Drivers

• Chronic disease prevalence
• Personalized medicine demand
• Biobanking tech advancements
• Genomic research growth

• Biobanking awareness - The growing awareness of biobanking as a critical driver in the global biobanks market reflects an increased recognition of the value these repositories provide to medical research and healthcare. Biobanks are essential for the collection, storage, and management of biological samples such as tissues, blood, and DNA, which are vital for advancing scientific understanding and developing new treatments. As more stakeholders, including researchers, healthcare providers, and the general public, become aware of the importance of biobanking, the demand for these facilities and their services is expected to rise.

  Enhanced biobanking awareness has been facilitated by various initiatives aimed at educating the public and professionals about the benefits of biobanking. Public campaigns, academic conferences, and industry seminars highlight the role of biobanks in facilitating breakthroughs in disease research, personalized medicine, and drug development. These efforts help demystify the biobanking process and underscore its potential to revolutionize healthcare by providing high-quality, well-preserved biological samples for research and clinical use.

  As awareness grows, so does participation in biobanking initiatives. Increased public willingness to donate biological samples contributes to more comprehensive and diverse biobanks, which in turn supports more robust and inclusive research. This heightened engagement not only enhances the quantity and quality of samples available but also fosters a collaborative environment where biobanks can thrive and expand their capabilities.

Restraints

• Ethical/legal issues
• Lack of standardization
• Data privacy concerns
• Skilled professional shortage

• Sample quality/storage issues - Sample quality and storage issues present significant restraints in the global biobanks market. The integrity of biological samples is crucial for reliable research and clinical outcomes, and any compromise in quality can severely affect the validity of scientific studies. Maintaining high-quality samples over extended periods requires stringent storage conditions, including precise temperature control, protection from contamination, and proper handling procedures. Any lapses in these conditions can lead to sample degradation, rendering them useless for research or clinical purposes.

  One of the primary challenges in biobanking is ensuring consistent and appropriate storage conditions. Biological samples are often sensitive to temperature fluctuations, light exposure, and microbial contamination. For instance, DNA samples need to be stored at specific temperatures to prevent degradation, and any variation can compromise their integrity. Tissue samples require careful handling and storage to maintain their structural and molecular characteristics. The cost and complexity of maintaining such controlled environments can be prohibitive, especially for smaller biobanks with limited resources.

  Standardization across biobanks is lacking, which further exacerbates quality issues. Different biobanks may follow varied protocols for sample collection, processing, and storage, leading to inconsistencies that can affect the comparability of samples. This lack of standardization can result in difficulties in pooling data from multiple biobanks for large-scale studies, ultimately limiting the scope and impact of biobanking initiatives.

Opportunities

• AI and big data integration
• Clinical trial biobank use
• Virtual biobank development
• Pharma partnerships

• Population-based biobank - The establishment and expansion of population-based biobanks represent significant opportunities in the global biobanks market. Population-based biobanks collect biological samples and health information from large cohorts of individuals within specific geographic regions or demographic groups. These biobanks aim to represent the diversity of the population and provide valuable resources for epidemiological studies, genetic research, and personalized medicine initiatives.

  One of the key opportunities presented by population-based biobanks is the ability to study the complex interplay between genetics, environment, and lifestyle factors in health and disease. By collecting samples from diverse populations, researchers can better understand the genetic and environmental determinants of various conditions, including common diseases, rare disorders, and traits. This information can lead to the identification of biomarkers, genetic risk factors, and novel therapeutic targets, ultimately facilitating the development of more effective preventive strategies and treatments tailored to individual patients.

  Population-based biobanks also enable longitudinal studies that track changes in health outcomes over time, providing valuable insights into disease progression, treatment responses, and the impact of interventions. These longitudinal datasets allow researchers to investigate the natural history of diseases, identify predictors of disease onset and progression, and evaluate the effectiveness of public health interventions. Longitudinal biobank data are particularly valuable for studying chronic diseases, aging-related conditions, and complex multi-factorial disorders.

Key players in Global Biobanks Market include,

• AMS Biotechnology Ltd
• ASKION GmbH
• Avantor Inc
• Azenta Inc
• Bay Biosciences LLC
• BioIVT & Elevating Science
• Boca Biolistics
• CTI Biotech
• Cureline Inc
• Firalis SA
• Geneticist Inc
• Hamilton Bonaduz AG
• Isenet Biobanking
• Merck & Co Inc
• ProteoGenex Inc
• Qiagen NV
• Stemcell Holdings Inc
• STEMCELL Technologies Inc
• Thermo Fisher Scientific Inc
• US Biolab Corp Inc

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis